Medication Source Code Verification: Student 2 (UPDATED 08/7/19)

[callahantiff]

Student (GitHub Username): @WhitleyMcCall Verification Number: 2

Assigned Domain Expert: @trinklek

Verification Task Description: DropBox Paper Documentation

Phenotype Descriptions: project wiki

Verification Assignments: UPDATES: this is replacing the original dashboard utilized by AVM (archived here)

Verification Assignments:

• [x] ADHD (~n=34,184~ n=6,837) -- #41 (completed by AVM)
• [ ] Appendicitis (~n=15,304~ n=3,061) -- #45
• [ ] Crohn’s Disease (~n=17,887~ n=3,577) -- #47
• [ ] Hypothyroidism (~n=15,243~ n=3,049) -- #48
• [ ] Peanut Allergy (n=57) -- #53
• [x] Steroid-Induced Osteonecrosis (~n=39,099~ n=7,820) -- #54
• [ ] Systemic Lupus Erythematosus (~n=23,816~ n=4,763) -- #55

[callahantiff]

UPDATE: @WhitleyMcCall and I decided during our meeting today that she will only re-verify the ADHD phenotype mappings (which @avnmatre mapped) if their is time (and it makes sense) after the rest of the phenotypes have been verified.

[trinklek]

UPDATE: @WhitleyMcCall and I decided during our meeting today that she will only re-verify the ADHD phenotype mappings (which @avnmatre mapped) if their is time (and it makes sense) after the rest of the phenotypes have been verified.

Sounds great and efficient!

[WhitleyMcCall]

@callahantiff @trinklek For now, I am leaving the "Not Phenotype Relevant" box unchecked for topical betamethasone in order for a discussion on possibly including it. Topical steroids are not part of the phenotype criteria, but as a moderate to very high potency steroid, topical betamethasone use can cause sufficient systemic absorption for HPA axis suppression, and long-term use poses a risk for systemic adverse effects, such as osteonecrosis. However, if including topical betamethasone in the phenotype definition we would likely need to define criteria (e.g. duration same as other routes at 14 days? all potencies/formulations?)

[trinklek]

@callahantiff @trinklek For now, I am leaving the "Not Phenotype Relevant" box unchecked for topical betamethasone in order for a discussion on possibly including it. Topical steroids are not part of the phenotype criteria, but as a moderate to very high potency steroid, topical betamethasone use can cause sufficient systemic absorption for HPA axis suppression, and long-term use poses a risk for systemic adverse effects, such as osteonecrosis. However, if including topical betamethasone in the phenotype definition we would likely need to define criteria (e.g. duration same as other routes at 14 days? all potencies/formulations?)

@WhitleyMcCall @callahantiff Great thought Whitley! Should we plan a call to discuss this and any other issues? I am out of the country 8/31-9/18 so perhaps before then? Let me know what works best for you all!

[WhitleyMcCall]

@callahantiff @trinklek What about a call next week or weekend? I'm free Thursday evening (8/22) and Friday evening (8/23) or any time Sat/Sun (8/24-25)